582 related articles for article (PubMed ID: 12912938)
21. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
22. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
Zheng S; Chen LR; Wang HJ; Chen SZ
Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
[TBL] [Abstract][Full Text] [Related]
23. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases.
Hisaoka M; Ishida T; Kuo TT; Matsuyama A; Imamura T; Nishida K; Kuroda H; Inayama Y; Oshiro H; Kobayashi H; Nakajima T; Fukuda T; Ae K; Hashimoto H
Am J Surg Pathol; 2008 Mar; 32(3):452-60. PubMed ID: 18300804
[TBL] [Abstract][Full Text] [Related]
24. Heterologous and rare homologous sarcomas of the uterine corpus: a clinicopathologic review.
Fadare O
Adv Anat Pathol; 2011 Jan; 18(1):60-74. PubMed ID: 21169739
[TBL] [Abstract][Full Text] [Related]
25. Fluorescence in Situ Hybridization (FISH) for Differential Diagnosis of Soft Tissue Sarcomas.
Asif A; Mushtaq S; Hassan U; Akhtar N; Hussain M; Azam M; Qazi R
Asian Pac J Cancer Prev; 2018 Mar; 19(3):655-660. PubMed ID: 29580035
[TBL] [Abstract][Full Text] [Related]
26. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
[TBL] [Abstract][Full Text] [Related]
28. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
29. Nonrhabdomyosarcoma soft tissue sarcomas in children: is age at diagnosis an important variable?
Hayes-Jordan AA; Spunt SL; Poquette CA; Cain AM; Rao BN; Pappo AS; Shochat SJ
J Pediatr Surg; 2000 Jun; 35(6):948-53; discussion 953-4. PubMed ID: 10873042
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.
Miettinen M; Lasota J
Pol J Pathol; 2003; 54(1):3-24. PubMed ID: 12817876
[TBL] [Abstract][Full Text] [Related]
31. Late effects of radiotherapy for pediatric extremity sarcomas.
Paulino AC
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):265-74. PubMed ID: 15337565
[TBL] [Abstract][Full Text] [Related]
32. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review.
Kirova YM; Vilcoq JR; Asselain B; Sastre-Garau X; Fourquet A
Cancer; 2005 Aug; 104(4):856-63. PubMed ID: 15981282
[TBL] [Abstract][Full Text] [Related]
33. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement.
Doyle LA; Wang WL; Dal Cin P; Lopez-Terrada D; Mertens F; Lazar AJ; Fletcher CD; Hornick JL
Am J Surg Pathol; 2012 Oct; 36(10):1444-51. PubMed ID: 22982887
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
35. Post-radiation sarcomas. Clinical outcome of 52 Patients.
Mavrogenis AF; Pala E; Guerra G; Ruggieri P
J Surg Oncol; 2012 May; 105(6):570-6. PubMed ID: 22012601
[TBL] [Abstract][Full Text] [Related]
36. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.
Sato O; Wada T; Kawai A; Yamaguchi U; Makimoto A; Kokai Y; Yamashita T; Chuman H; Beppu Y; Tani Y; Hasegawa T
Cancer; 2005 May; 103(9):1881-90. PubMed ID: 15772959
[TBL] [Abstract][Full Text] [Related]
37. Rhabdomyosarcoma arising in a previously irradiated field: an analysis of 43 patients.
Dang ND; Teh BS; Paulino AC
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):598-603. PubMed ID: 22836049
[TBL] [Abstract][Full Text] [Related]
38. Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases.
Sheppard DG; Libshitz HI
Clin Radiol; 2001 Jan; 56(1):22-9. PubMed ID: 11162693
[TBL] [Abstract][Full Text] [Related]
39. Groin angiosarcoma following radiotherapy for vulvar cancer.
Sanz C; Moreno F; Armas A; Casado A; Castillo MC
Gynecol Oncol; 2005 May; 97(2):677-80. PubMed ID: 15863181
[TBL] [Abstract][Full Text] [Related]
40. Postradiation soft tissue sarcomas. An analysis of 53 cases.
Laskin WB; Silverman TA; Enzinger FM
Cancer; 1988 Dec; 62(11):2330-40. PubMed ID: 3179948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
